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Abstract
Background: β-blocker treatment has emerged as an effective treatment modality for heart
failure. Interestingly, β-blockers can activate both pro-apoptotic and anti-apoptotic pathways.
Nevertheless, the mechanism for improved cardiac function seen with β-blocker treatment
remains largely unknown. Carvedilol is a non-selective β-blocker with α-receptor blockade and
antioxidant properties. We therefore studied the impact of the effects of carvedilol in an animal
model of end-stage heart failure.
Results: To test whether chronic treatment with β-blockade decreases apoptosis, we treated
myopathic turkeys with two dosages of carvedilol, 1 mg/kg (DCM1) and 20 mg/kg (DCM20), for four
weeks and compared them to non-treated DCM animals (DCM0) and to control turkeys (CON).
Echocardiographic measurements showed that non-treated DCM animals had a significantly lower
fractional shortening (FS) when compared to CON (68.73 ± 1.37 vs. 18.76 ± 0.59%, p < 0.001).
Both doses of carvedilol significantly improved FS (33.83 ± 10.11 and 27.73 ± 6.18% vs. 18.76 ± 0.59
% for untreated DCM, p < 0.001). DCM left ventricles were characterized by a higher percentage
of apoptotic nuclei when compared to CON (5.64 ± 0.49 vs. 1.72 ± 0.12%, respectively p < 0.001).
Both doses of carvedilol significantly reduced the number of apoptotic nuclei (2.32 ± 0.23% and
2.36 ± 0.26% 1 mg and 20 mg/kg respectively).
Conclusions: Carvedilol improves ventricular function. Furthermore, treatment with carvedilol
decreased the incidence of apoptosis in cardiac myocytes from failing hearts at both doses. These
data suggest that the inhibition of apoptosis with carvedilol may lead to improvement in ventricular
function and may underlie a beneficial effect of β-blockade independent of heart rate lowering
effects.
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Loss of myocytes is thought to contribute to the progres-
sive decline in left ventricular function and the develop-
ment of congestive heart failure. Recent studies have
proposed that myocyte loss in cardiomyopathy can occur
by apoptosis without an inflammatory response
[reviewed in [1–3]]. In heart failure, growth stimulation
initially occurs as a compensatory effort to meet chroni-
cally altered hemodynamic demands and is mediated by
systemic and/or local up-regulation of mediators of
adrenergic pathways and by various cytokines [4,5]. How-
ever, cytokines can be directly toxic to cardiac myocytes
and result in increased apoptotic cell death [3,6]. Local
up-regulation of angiotensin II induces immediate-early
genes, which may lead to increased protein synthesis and
myocardial hypertrophy or, alternatively, may up-regulate
expression of apoptotic proteins (such as p53) in cardiac
myocytes. The initial increase in circulating norepine-
phrine is thought to maintain cardiac function through
inotropic mechanisms. However, a direct cardiac myocyte
toxicity from norepinephrine is well recognized [6,7]. Fur-
thermore, pressure-overload and stretch associated release
of angiotensin II has been shown to induce myocyte
apoptosis [8–10]. In an elegant paper by Telger et al., it
has clearly been demonstrated that cardiac hypertrophy is
initially preceded by a wave of apoptosis of cardiac myo-
cytes followed by cell growth and a decrease in pro-
grammed cell death [10]. Apoptosis may, therefore, be the
consequence of prolonged growth stimulation (adrener-
gic and renin-angiotensin axes) of adult cardiac myocytes,
which are terminally differentiated. Similarly, certain
cytokines (such as tumor necrosis factor) can induce
growth as well as apoptosis [11]. As proposed by Telger et
al. it is becoming clear that cell growth and programmed
cell death are in fact two linked processes [10].
Over the last five years, β-blocker therapy has become one
of the main treatment modalities for heart failure. Of par-
ticular interest is the use of carvedilol [12–16]. Carvedilol
is a novel multiple-action neurohormonal antagonist. Its
primary activities are nonselective β-adrenoceptor block-
ade, vasodilatation (mediated through α1-adrenoceptor
blockade), and antioxidant activity [12]. In many clinical
studies, carvedilol has been shown to improve left ven-
tricular function and symptoms in patients with ischemic
heart disease or idiopathic dilated cardiomyopathy [13–
16] and to dramatically reduce mortality [17]. However, it
remains unclear how carvedilol improves ventricular
function in heart failure.
In an animal model of cardiomyopathy that has many
similarities to human heart failure, we tested the hypoth-
esis that a reduction in apoptosis may be responsible for
the beneficial effects of carvedilol. As such, attenuation of
apoptosis in the myocardium may represent a novel and
important mechanism that contributes beneficial effects
on the myocardium.
Results
Baseline Characteristics of Dilated Cardiomyopathic 
Animals
We have previously shown that removal of furazolidone
from the feed after three weeks results in progressive car-
diac dilatation and heart failure [18]. At the time of rand-
omization of the DCM group into three groups i.e., DCM0
(no treatment), DCM1 (lower dose carvedilol) or DCM20
(higher dose carvedilol), fractional shortening was not
different between the groups (p > 0.1). Evidence for severe
heart failure was marked by significantly reduced left ven-
tricle fractional shortening (controls 63.67 ± 1.04% n = 34
vs. DCM 11.95 ± 0.59% n = 18, p < 0.001).
Effect of Carvedilol on Ventricular Function
We investigated the effect of carvedilol by administering
two different dosages (1 mg and 20 mg/kg body weight
per day) to control and DCM turkeys for four weeks. We
studied two dosages (pharmacological and non-pharma-
cological) as a difference in dose-dependency for cardiac
function improvement has previously been demonstrated
by us with another non-selective beta-blocker [18]. Fur-
thermore, we wanted to determine if carvedilol might
exert beneficial effects independent of heart rate effects.
The lower dose (1 mg/kg) did not reduce heart rate. How-
ever, the higher dose reduced HR by approximately 15%
for 8 hours.
In vivo contractile performance of the heart was assessed
by the determination of fractional shortening of the left
ventricle. As shown in Table 1 and Figure 1, fractional
shortening was increased by 32 and 45% in DCM1 and
DCM20 animals, respectively, compared to non-treated
DCM animals (DCM0). Compared with baseline values at
the time of randomization, the improvement in fractional
shortening was of 57% in DCM1 and 65% in DCM20.
Associated with improved cardiac function was a reduc-
tion in the incidence of apoptotic nuclei (see below).
The body weight was significantly decreased in DCM ani-
mals compared to control animals (p < 0.001 compared
to control) (Table 2). This animal model is associated
with cachexia. Carvedilol treatment resulted in a slight
gain of body weight, 15% in the DCM1 group and 20% in
the DCM20 group compared with the non-treated DCM
group (DCM0). Carvedilo also increased the body weight
of control animals (p < 0.001). These data indicate a favo-
rable effect on cachexia. In non-treated DCM animals the
hearts weighed significantly less than control hearts (p =
0.01). DCM animals treated with carvedilol showed a sig-
nificant increase in HW compared to hearts from non-
treated DCM animals (p < 0.001). Therefore the HW/BWPage 2 of 9
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animals compared to hearts from non-treated DCM ani-
mals. Interestingly, the HW/BW ratio was lower for
carvedilol treated control animals compared to non-
treated control animals. Left ventricle volume was signifi-
cantly larger for non-treated DCM hearts. Carvedilol sig-
nificantly decreased LV volume at both dosages.
Effect of Carvedilol on Cardiac Myocyte Apoptosis
Evaluation of tissue sections by the TUNEL technique
revealed only small numbers of TUNEL-positive cells in
the control hearts (Table 1 and Figure 2A). Hearts from
DCM animals had a significant increase in the number of
TUNEL-positive cells compared to controls (5.64 ± 0.49%
vs. 1.72 ± 0.12% DCM and control respectively, p <
0.001), indicating the occurrence of apoptosis (Figure
2B).
In contrast to non-treated DCM hearts, myocardial tissue
sections prepared from hearts from animals treated with
carvedilol showed a significant reduction in the numbers
of TUNEL-positive myocyte nuclei. An example of such an
observation is depicted in Figure 3A and 3B (DCM1 and
DCM20 respectively). Both the lower and the higher doses
of carvedilol were effective in reducing apoptosis from
5.64 ± 0.49% in non-treated DCM animals to almost con-
trol levels 2.32 ± 0.23% (DCM1) and 2.36 ± 0.26%
(DCM20), p < 0.001, compared to DCM0 respectively (Fig-
ure 3C).
Discussion
Effect of Carvedilol on a Heart Failure Model
The furazolidone-induced turkey model is a well charac-
terized experimental model of dilated cardiomyopathy
with features very similar to those found in human heart
failure [19–22]. Decreased contractile function (reduced
fractional shortening of the left ventricle) and morpholog-
ical changes (increased heart volumes, left ventricular dil-
atation, and myocyte hypertrophy) are characteristic
features of this model [21,22].
β-blocker treatment has emerged as an effective treatment
modality for heart failure. Both in animal and human
studies of heart failure, β-adrenergic blockade interven-
tion appears to have beneficial effects on cardiac myocyte
function [1,23,24]. Of particular importance, studies
using carvedilol have shown remarkable improvements in
cardiac performance [12,13,15,16] and reduction in mor-
tality in humans [17]. We have previously shown that pro-
pranolol, a nonselective β-blocker, is cardioprotective and
prevents the development of heart failure in turkeys when
given concurrently with furazolidone [21]. Similarly,
carteolol, a nonselective β-blocker, resulted in improve-
ment in ejection fraction, reduction in ventricular vol-
umes, an increase in developed pressure as well as an
increase in rate of survival in our turkey model [18].
Improvement in cardiac function was associated with cel-
lular remodeling of cardiac myocytes. Cardiac myocytes
from hearts treated with a non-selective β-blocker i.e.,
Table 1: Inhibition of Apoptosis by Carvedilol Correlates with Improvement in LV Function.
Cont n = 13 Cont1 n = 11 Cont20 n = 10 DCM0 n = 18 DCM1 n = 13 DCM20 n = 12
FS % 68.73* ± 1.37 66.09* ± 0.90 66.99* ± 1.37 18.76 ± 1.83 27.73* ± 6.18 33.83* ± 10.11
Apoptosis % 1.72* ± 0.12 2.10 * ± 0.25 2.20* ± 0.24 5.64 ± 0.49 2.32* ± 0.23 2.36* ± 0.26
Fractional shortening (FS%) was calculated from echocardiographic images as described in the methods. Apoptotic nuclei were counted as 
described in methods. *p < 0.001 compared to DCM0.
Effect of carvedilol on fractional shortening (FS) of the left ventricleFigure 1
Effect of carvedilol on fractional shortening (FS) of 
the left ventricle. Carvedilol administration is associated 
with a improvement in left ventricular function DCM0 (n = 
18), DCM1 (n = 13), DCM20 (n = 12). *p < 0.001 compared to 
DCM0. Healthy control turkeys (CON); control turkeys 
treated with two dosages of carvedilol, 1 mg/kg (CON1) and 
20 mg/kg (CON20); dilated cardiomyopathic turkeys (DCM); 
non-treated DCM animals (DCM0); myopathic turkeys 
treated with two dosages of carvedilol, 1 mg/kg (DCM1) and 
20 mg/kg (DCM20).Page 3 of 9
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energetics, normal β1 receptor density as well as regression
of myocyte hypertrophy and reduced connective tissue
content [18]. Furthermore, administration of carteolol
has been reported to prevent the development of virally
induced cardiomyopathy in a murine model [25]. In a
canine model with left ventricular dysfunction produced
by multiple sequential intracoronary microemboliza-
tions, long term treatment with metoprolol, a β1-selective
blocker, has been reported to prevent the progression of
LV systolic dysfunction and LV chamber dilatation [26].
Similarly, our present findings on the effect of carvedilol
indicated improvement of left ventricular function and
smaller LV volumes. Carvedilol prevented progression of
LV systolic dysfunction and LV dilatation as previously
reported in other models using β-blockers [18,26].
Animals with dilated cardiomyopathy which received
carvedilol showed significant improvement in LV systolic
function after 4 weeks. Notably, the improvement of LV
systolic function in animals treated with carvedilol was
associated with a decrease of LV volumes compared with
non-treated DCM animals. Importantly, both doses of
carvedilol improved LV contractile performance. Frac-
tional shortening (%) was increased by an average of
approximately 38% and impressively by 80% in some
individual animals. These data seem to agree with the
results of human clinical studies, and are suggestive that
carvedilol not only slows deterioration of cardiac func-
tion, but also improves cardiac function.
The trend that the 20 mg/kg body weight dose might not
have been well tolerated was demonstrated by some ani-
mals becoming moribund for a short period after dosing
which might be due to a reduction in heart rate and car-
diac output with resultant reflect tachycardia. We have
previously shown a negative force-interval relationship
(i.e., negative treppe) in failing hearts with this model
[18]. This is in line with data from human studies, which
showed that when first administered, β-blockers actually
slow heart rate and diminish ejection fraction [27]. The
higher dose of carvedilol significantly reduced heart rate
and blood pressure for up to eight hours. Animals that tol-
erated the higher dose did nevertheless benefit from the
treatment. This is similar to human clinical studies where
greater benefit is derived from higher dosages, if tolerated
[28].
Apoptosis in Animal Models of Heart Failure
Heart failure is characterized by progressive deterioration
of global left ventricular function over time. The mecha-
nisms responsible for the worsening of cardiac function
are not clear. Loss of cardiac myocytes has been suspected
to be a feature of the cardiomyopathic process that con-
tributes to progressive decline in left ventricular function
and the development of congestive heart failure [29]. Evi-
dence supporting the concept of myocyte apoptosis occur-
rence and contribution in the progression of heart failure
has been obtained from a variety of observations, includ-
ing in vitro studies, experimental animal models of cardiac
dysfunction, and studies on cardiac tissue obtained from
patients with end-stage heart failure [5,7–9,29].
We sought to evaluate the incidence and the extent of
apoptosis in our animal model of heart failure. Using the
TUNEL technique as a means of detection, we were able to
document the occurrence of apoptosis in ventricles from
failing hearts, which was characterized by a higher per-
centage of apoptotic nuclei when compared to controls
(5.64% vs. 1.72%). These apoptotic indexes are within the
Table 2: Effect of Carvedilol on Gross Morphology
HW (kg) BW (kg) HW/BW (%) LV vol (ml)
Control (n = 13) 0.018  ± 0.001 4.36# ± 0.16 0.4  ± 0.013 0.24• ± 0.04
Cont1 (n = 11) 0.018  ± 0.001 5.3# ± 0.14 0.35  ± 0.016 0.37• ± 0.06
Cont20 (n = 10) 0.02  ± 0.001 5.65# ± 0.09 0.35  ± 0.008 0.37• ± 0.04
DCM0 (n = 18) 0.017 ± 0.001 2.61 ± 0.23 0.64 ± 0.049 9.36 ± 2.0
DCM1 (n = 13) 0.019  ± 0.001 3.07# ± 0.29 0.60  ± 0.05 6.28• ± 2.54
DCM20 (n = 12) 0.019  ± 0.001 3.26# ± 0.29 0.58  ± 0.078 5.38• ± 1.95
HW: heart weight  p ≤ 0.01 compared to non-treated DCM group; BW: body weight #p < 0.001 compared to non-treated DCM group; HW/
BW ratio  p < 0.04 compared to non-treated DCM group; LV vol: atria were removed and the left ventricles were arrested in diastole and filled 
with saline • p ≤ 0.008 compared to non-treated DCM. Note the increase in body weight and heart weight with carvedilol treatment. This resulted 
in a significant improvement in HW/BW ratio despite having heavier hearts. The reduction in heart weight seen in the non-treated DCM group was 
associated with a higher incidence of apoptosis while the increased heart weight in hearts from DCM animals treated with carvedilol was associated 







Page 4 of 9
(page number not for citation purposes)
BMC Physiology 2003, 3 http://www.biomedcentral.com/1472-6793/3/6range of values in heart failure reported in the literature
(0.2% to 35%) [3,30–33]. The high degree of variability
reported in the literature in the magnitude of apoptosis
Detection of apoptotic cells by fluorescence microscopyFigure 2
Detection of apoptotic cells by fluorescence micros-
copy. The TUNEL assay with fluorescein as the tag was used 
to stain the nuclei of apoptotic cells in frozen cardiac sec-
tions. (A) Control heart (containing essentially no TUNEL-
positive cells in this field) and (B) a fluorescent micrograph of 
a representative field from a failing heart (DCM) containing a 
higher number of apoptotic nuclei. Micrographs were taken 
with 40X objective and reduced for reproduction.
Effect of carvedilol on cardiac myocyte apoptosisFigure 3
Effect of carvedilol on cardiac myocyte apoptosis. 
Failing hearts treated with carvedilol show reduced number 
of TUNEL-positive nuclei, (A) DCM1 and (B) DCM20. Both 
low and high doses of the drug inhibited myocyte apoptosis 
to almost control levels (C). No effect of carvedilol on apop-
tosis in control groups was observed (C). *p < 0.001 vs. con-
trol and carvedilol treated groups. Micrographs in (A) and (B) 
were taken with 40X objective and reduced for 
reproduction.Page 5 of 9
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used to quantify apoptotic nuclei.
When reporting apoptotic nuclei using the TUNEL assay,
two observations should be considered; 1) although
apoptosis occurred in our model of heart failure, we might
have missed, in random histological sections, evidence of
apoptosis thereby under estimating the severity of pro-
grammed cell death due to the fact that apoptotic cells
undergo rapid phagocytosis with the entire process lasting
less than two hours in some cell systems [34], and 2)
apoptosis in the present study was evaluated at a single
time point when the heart was still undergoing LV remod-
eling. Hence, the documentation of apoptosis at this stage
may not reflect the true magnitude of its occurrence dur-
ing the initiation and transition to heart failure. In a rat
model of pressure-overload hypertrophy produced by
aortic banding, apoptosis appeared to peak at four days
and gradually subsided after one month of aortic banding
[9]. Therefore, a longitudinal study of apoptosis in failing
hearts from initiation to transition to failure is worth pur-
suing. In this way, the incidence of apoptosis can be doc-
umented as the heart moves progressively from normal to
compensated hypertrophy and finally to overt decompen-
sated heart failure. These animals were in compensated
heart failure and, often in the non-treated group, went
into decompensated heart failure when stressed during
echocardiographic examination.
With improved cardiac function, there should be a reduc-
tion in activation of the adrenergic-renin-angiotensin axes
as well as a decrease in activated cytokines such as tumor-
necrosis factor-α. In our model of heart failure, cardiac
function correlated with the incidence of apoptosis. As
described in Table 1 and Figure 3, there were a higher
number of apoptotic cells in hearts with a reduction in
fractional shortening. In contrast, control hearts with nor-
mal ventricular function showed low rates of apoptosis.
The extent and occurrence of apoptosis may partially
explain the lack of an overall increase in heart weight in
hearts from non-treated DCM animals, despite a pro-
nounced increase in heart size. These observations, and
the results from several animal models, demonstrate that
apoptotic cells are present in failing hearts, suggesting that
apoptosis might be a mechanism involved, at least in part,
in the progression of heart failure and the reduction of
myocyte mass.
Carvedilol Inhibition of Apoptosis and Improvement of 
Ventricular Function
The extent of apoptosis in cardiomyopathic animals was
significantly reduced by treatment with carvedilol. Both
the lower and higher doses of carvedilol were effective in
decreasing the rate of apoptosis (approximately a 58%
reduction). This observation represents an important
finding in demonstrating the effectiveness of a cardiovas-
cular drug to protect against continual cardiac myocyte
apoptosis in failing hearts in vivo. Furthermore, the inhibi-
tion of apoptosis by carvedilol was accompanied by signs
of improvement in left ventricular function and heart size
(i.e. reduced LV volume) in the myopathic animals.
Whether the improved function, small heart size and
decreased wall stress were responsible for a reduction in
apoptosis is not known. However, the derived cardiac
benefit was independent of heart rate effects because ben-
efit was obtained at both dosages.
Our data support the conclusions of Rossig et al. in
endothelial cells. They reported levels of apoptotic cells
for control and NYHA III-IV hearts that were similar to our
observations [35]. We similarly believe that the suppres-
sion of apoptosis by carvedilol is likely due to its antioxi-
dative properties rather than the β-blocking effects [35].
We base this on our observation that a similar reduction
in the incidence of apoptosis was seen at both a non-phar-
macological (no effect on heart rate or blood pressure) as
well as a pharmacological dose of carvedilol. In a canine
model of chronic heart failure produced by multiple
sequential intracoronary embolizations, metprolol, a β1
selective blocker, reduced the incidence of apoptosis sup-
porting our experimental observations with carvedilol
[36]. The incidence of apoptosis was 5.32 ± 0.77 in heart
failure animals that were not treated which is similar to
our findings of 5.64 ± 0.49 in hearts from untreated ani-
mals with heart failure. Recently, Li et al. have demon-
strated that spontaneously hypertensive rats (SHR) with
symptoms of heart failure had significantly higher levels
of apoptotic myocytes than control myocytes [37]. When
treated with an angiotensin-converting enzyme inhibitor,
the number of apoptotic cells in the SHR with symptoms
of heart failure was dramatically reduced to control levels;
controls were SHR without symptoms of heart failure
[37]. Kajstura et al. have also reported that angiotensin II
increased the percentage of apoptotic cells in isolated
adult rat ventricular myocytes, and this effect was medi-
ated by AT-1 receptors [38]. Although ventricular function
was not assessed in these studies, the observations raise
the possibility that, like our findings with carvedilol, the
beneficial effect of ACE-inhibitors or AT-1 receptor block-
ers in heart failure may in part be attributed to an inhibi-
tion of myocyte apoptosis with a resultant improvement
in in vivo cardiac function, a concept that needs further
study.
The data presented suggest that attenuation of apoptosis
may underlie the beneficial effect of β-blockade on ven-
tricular function, and that the inhibition of apoptosis can
possibly lead to improvement in ventricular function.
This represents a novel mechanism to slow the progressive
deterioration of myocardial function that can occur inPage 6 of 9
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icals play a role in inducing cell apoptosis [39] and the
potent antioxidant property of carvedilol [12], we specu-
late that the beneficial effects attributed to carvedilol (i.e.
inhibition of apoptosis and improvement of LV function)
are mediated, in part, by its prevention of oxygen-derived
free radical damage [35,40]. Our data supports this idea.
Therapeutic Significance
With the clear demonstration that cardiac myocyte apop-
tosis is present in our heart failure model strategies for
prevention of apoptosis can be tested. The clinical consen-
sus has been that higher doses of β-blockade should incur
more benefits on ventricular remodeling. However, our
studies demonstrated similar benefits at a therapeutic and
sub-therapeutic dose. In light of the beneficial effect of
carvedilol on the progression of heart failure, and its
unique multi-actions that are not shared by any other β-
blocking drug or by any other agent currently used in the
treatment of heart failure, our findings represent an
important new mechanism of improved cardiac function.
The development of animal models of heart failure in
which apoptosis is an important feature will allow the
modulation of cell death pathways through targeted inter-
ventions. Understanding the role of specific signaling
pathways in cardiac myocyte apoptosis and developing
strategies to manipulate these intracellular pathways may
provide in the near future novel therapeutic approaches
for the management of heart failure.
Conclusions
In conclusion, our model of heart failure, which shows a
high level of congruence with the human condition, has
been shown to have a high level of apoptosis that corre-
sponds with cardiac failure. Carvedilol, a non-selective β-
blocker with α-blocking properties as well as antioxidant
properties, significantly reduced the incidence of pro-
grammed cell death while improving cardiac function.
This effect was independent of heart rate lowering effects,
i.e. β-blockade. The beneficial effects of carvedilol can
therefore be obtained with subtherapeutic doses. This is a
novel observation and important in treating patients who
may not tolerate higher doses (heart rate and blood pres-
sure lowering) of carvedilol. The apoptotic process is
linked to the development and progression of heart fail-




One day-old broad-breasted white turkey poults,
obtained from a commercial breeder, were wing-banded
for easy identification. At seven days of age, they were
weighed and randomly divided into two groups using a
random number generator. The control group (n = 34)
was maintained on a normal ration, free from any addi-
tives, and the experimental group (n = 91) was fed 700
parts per million furazolidone (Fz) for three weeks. Fura-
zolidone was stopped after day twenty-eight and the ani-
mals were randomized into three groups: one group did
not receive carvedilol treatment, DCM0 (n = 52), whereas
the other two groups, DCM1 (n = 19) and DCM20 (n = 20),
were treated with carvedilol in the same dosages as respec-
tive aged-matched control animals (see following). Simi-
larly, age matched control animals were randomized into
three groups: one group received no pharmacological
agent (Con0. n = 13), whereas the other two groups
received different dosages of carvedilol, 1 mg/kg (Con1 n
= 11) or 20 mg/kg body weight (Con20 n = 10). The lower
dose of carvedilol did not lower heart rate or blood pres-
sure. However, the higher dose of carvedilol resulted in a
significant reduction in heart rate (15%) and blood pres-
sure (9%) for up to eight hours. We performed dose range
studies using nine concentrations of carvedilol (data not
shown). At the time of euthanasia, body weights, heart
weights (after removal of the atria), and LV volumes were
obtained on all experimental animals.
Echocardiographic Measurements
Echocardiographic views were obtained using a 7.5 MHz
transducer on unsedated and quietly resting animals. Sev-
eral cardiac cycles were recorded on a videotape and the
two dimensional images subsequently played back for
analysis. Diastolic left ventricular internal dimension
(LVIDd) and systolic left ventricular internal dimension
(LVIDs) were also measured and used to determine the
fractional shortening. Fractional shortening (%) of the left
ventricle was calculated as (LVIDd - LVIDs/ LVIDd) × 100.
TUNEL
Randomly selected hearts from control and cardiomyo-
pathic turkey poults were rapidly removed, flushed with
PBS and infused with a tissue embedding medium (Tis-
sue-Tek, OCT Compound, Miles Inc., Elkhart, IN) and fro-
zen in liquid nitrogen. Serial 7 µm cross-sections from
heart blocks were cut and fixed to coated slides. Frozen
heart sections were fixed in 10% neutral formalin (4% for-
maldehyde) for 10 minutes at room temperature and
post-fixed in Methanol/Acetone (1:1) for 10 minutes at -
20°C. Detection of apoptotic cardiac myocytes was
achieved by direct immunofluorescence detection of dig-
oxigenin-labeled genomic DNA using the ApopTag Plus
in Situ apoptosis detection kit – Fluorescein (Intergen,
Purchase, NY). This method used the TUNEL technique to
stain DNA fragments in nuclei of apoptotic cells. Tissue
sections were then counter-stained with Hoechst 33258
stain (1 µg/ml) (Sigma), and viewed with an epifluores-
cence microscope (Zeiss Axiophot) equipped with filter
sets for fluorescein and Hoechst staining. To quantifyPage 7 of 9
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fields per section were examined. The percentage of apop-
totic cells was determined by counting the total number of
nuclei and TUNEL positive nuclei (apoptotic myocytes).
Samples were numbered to conceal the identity of differ-
ent groups during counting. Sections of interest were pho-
tographed using a microscope-integrated 35-mm camera.
Statistical Analysis
Data given in the text are means ± SD. The difference
between the means was evaluated using student's t test. P
< 0.05 was considered significant.
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